Search Within

Daniel C Danila

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (88)
  2. Journal Article (62)
  3. Book Section (1)
  4. Correspondence (1)
  5. Miscellaneous (1)
  6. Review (1)
Groups
  1. Department of Medicine (154)
  2. Genitourinary Oncology Service (154)
  3. Solid Tumor Oncology Division (154)
  4. GSK Faculty (50)
  5. Hematologic Malignancies, Division of (48)
  6. Epidemiology and Biostatistics (42)

More Groups

People
  1. Howard Scher (111)
  2. Michael Morris (53)
  3. Martin Fleisher (48)
  4. Dana Rathkopf (45)
  5. Susan Slovin (39)
  6. Aseem Anand (33)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (9)
  4. 2022 (8)
  5. 2021 (12)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (73)
  2. Clinical Cancer Research (11)
  3. Annals of Oncology (10)
  4. Cancer Research (7)
  5. European Urology (5)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (78)
  2. American Association for Cancer Research (20)
  3. Elsevier Science, Inc. (15)
  4. Oxford University Press (11)
  5. Elsevier Inc. (8)
  6. Society of Nuclear Medicine (3)

More Publishers

Results (154)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer
    Meeting Abstract

    Hirani, R.; Nandakumar, S.; Kalidindi, T.; Fidele, D.; Rajanala, H.; Mazzu, Y.; Yoshikawa, Y.; Jehane, L.; Lee, G. S. M.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide
    Journal Article

    Brown, L. C.; Halabi, S.; Schonhoft, J. D.; Yang, Q.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Barnett, E. S.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W. K.; Pook, D. W.; Appleman, L. J.; Waterhouse, D. M.; Horvath, L.; Edenfield, W. J.; Matsubara, N.; Danila, D. C.; Aggarwal, R. R.; Petrylak, D. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Hirani, R.; Nandakumar, S.; Kalidindi, T. M.; Fidele, D.; Rajanala, S. H.; Mazzu, Y. Z.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J. L.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study
    Journal Article

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W. K.; Danila, D. C.; Edenfield, W. J.; Aggarwal, R. R.; Petrylak, D. P.; Sartor, A. O.; Sumey, C. J.; Dorff, T. B.; Yu, E. Y.; Adra, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save